|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these reaults suggest that the PTEN/FOXO3a/PLZF signalling pathway may be capable of inhibiting growth and metastasis in PC by regulating VEGF-mediated angiogenesis, which requires further in vivo and in vitro studies and can potentially be a therapeutic target for PC.
|
31087222 |
2020 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer.
|
30333153 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over-expression of several growth factors, most notably vascular endothelial growth factor (VEGF), has been implicated in PC resulting in dysfunctional signal transduction pathways and the facilitation of tumor growth, invasion and metastasis.
|
30914029 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
For example, propofol down-regulates the expression of vascular endothelial growth factor to inhibit pancreatic cancer malignancy.
|
30861616 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, this study proposes a potential molecular mechanism illustrating that β‑elemene can block the HIF1A/VEGFA pathway, thereby inhibiting the generation of peritoneum effusion in pancreatic cancer based on network pharmacology analysis, and further highlights the importance of targeting the HIF1A/VEGF pathway as a therapeutic approach to treat peritoneum effusion in patients with pancreatic cancer.
|
31638231 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
We concluded that tumor size and mutated VEGF pathway in PC are important factors affecting PDX model construction with NSG mice.-Guo, S., Gao, S., Liu, R., Shen, J., Shi, X., Bai, S., Wang, H., Zheng, K., Shao, Z., Liang, C., Peng, S., Jin, G. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer.
|
30091943 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data provide evidence that PGE2 may be an important mediator between COX-2 and VEGF expression in the process of angiogenesis in pancreatic cancer.
|
29963167 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival.
|
30027561 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a Cox model regression our study demonstrates that VEGF-R1/VEGF-R2 coexpression might be considered as a poor prognostic factor in pancreatic cancer.
|
28338114 |
2017 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human pancreatic cancer cells (Miapaca-2 and Panc-1) in vitro and murine pancreatic cancer cell (Panc02) in vivo were used to assess the effect of propofol on vascular endothelial growth factor (VEGF) expression and migration of pancreatic cancer cells.
|
27986626 |
2017 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, the authors interrogate the proteome of pancreatic cancer endothelium via phage display and identify hornerin as a critical protein whose expression is essential to maintain the pancreatic cancer vasculature through a VEGF-independent mechanism.
|
28916756 |
2017 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
RON and vascular endothelial growth factor (VEGF) overexpression in resected left-sided pancreatic cancer was also evaluated by immunohistochemistry using pre-diluted anti-RON and anti-VEGF antibodies.
|
28943931 |
2017 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis using Universal exPress Codes (UPCs) with the public microarray database GEO indicates significantly higher mRNA expressions of VEGF-A, bFGF, and bFGFR2 in pancreatic cancers than those in normal pancreatic tissues.
|
26820381 |
2016 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest TLR4 may promote angiogenesis in pancreatic cancer by activating the PI3K/AKT signaling pathway to induce VEGF expression.
|
27426724 |
2016 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To clarify the relevance of these observations in vivo, we demonstrate that many human pre-malignant pancreatic intraepithelial neoplasms and frank pancreatic cancers express substantial levels of DUOX protein compared to histologically normal pancreatic tissues, and that expression of both DUOX2 and VEGF-A mRNAs is significantly increased in surgically-resected pancreatic cancers compared to the adjacent normal pancreas.
|
27637085 |
2016 |
|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The vascular endothelial growth factor (VEGF) has a strong influence in tumor-related angiogenesis having association with the grade of angiogenesis and the prognosis of different solid tumors including pancreatic cancer.
|
23719599 |
2014 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, establishment of pancreatic cancer in mice exposed to chronic stress was accompanied by up-regulation of the expression of MMP-2, MMP-9, and VEGF, mediated by a HIF- 1α-dependent β-AR signaling pathway.
|
23745588 |
2013 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TPL inhibited the proliferation of pancreatic cancer cells in a time and concentration-dependent manner and decreased the expression of COX-2 and VEGF in vitro.
|
23924856 |
2013 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma VEGF-A and VEGFR-2 are potential predictive markers for bevacizumab efficacy, supporting findings in gastric and pancreatic cancers.
|
23422754 |
2013 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF targeted gene silencing approach has the potential to serve as a novel treatment for pancreatic cancer.
|
23254994 |
2013 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The simultaneous RNA interference‑mediated downregulation of survivin and VEGF expression inhibited proliferation and induced the apoptosis of Panc‑1 cells and HUVECs, indicating that combined therapy with survivin and VEGF inhibition may serve as a potential strategy for the treatment of pancreatic cancer.
|
23467576 |
2013 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the antitumor and biologic effects of BIBF 1120 (nintedanib), a tyrosine kinase inhibitor that targets VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor in preclinical models of lung and pancreatic cancer, including models resistant to VEGF-targeted treatments.
|
23729403 |
2013 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Vascular endothelial growth factor receptors (VEGFRs) are expressed not only by endothelial cells but also by pancreatic cancer cells.
|
22207048 |
2012 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
|
22906006 |
2012 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ultimately, systemic administration of the nanoparticles carrying vascular endothelium growth factor (VEGF) siRNA led to the significant reduction in the subcutaneous BxPC3 tumor growth, well consistent with the enhanced accumulation of siRNA and the significant VEGF gene silencing (~68%) in the tumor.
|
22580114 |
2012 |